释 义 n. 高镁血症
例 句 There is no hypermagnesemia with apparent clinical effect by these doses of magnesium sulfate during operation. 应用本实验剂量的硫酸镁不会造成有临床效应的高镁血症。
大鼠高镁血症紊乱，无相关性: 十五肽BPC 157 abrogates，L-NAME和L-精氨酸恶化
作者： Maria Medvidovic-Grubisic
The beneficial effect of pentadecapeptide BPC 157 (no muscle weakness, markedly counteracted brain lesions, lessened hypermagnesemia, maintained normokalaemia) is common for a lg–ng/kg dose range and is significant, because the same doses used and beneficial effects were previously noted. Furthermore, combined hyperkalaemia/hypermagnesemia consistently appeared along with worsening and then disappeared with amelioration, indicating that clearly attenuated hypermagnesemia/maintained normokalaemia is suggestive that BPC 157 might, here, also counteract the initial event leading to hypermagnesemia. A supportive analogy is the counteraction of magnesium sulfate-induced writhing that also appears rapidly and is quite specific as it is unaffected by anti-inflammatory drugs (including serotonin and histamine receptor antagonists) and is unaccompanied by prostaglandin release. This effect, along with the illustrative evidence, implies all of the counteracting effects mentioned before (i.e., on paralysis, arrhythmias, and hyperkalaemia, and extreme muscle weakness; parasympathetic and neuromuscular blockade; injured muscle). In contrast, with a worsened course, higher hypermagnesemia, and emerging hyperkalaemia, it is likely that both LNAME and L-arginine might adversely affect the same events (and that these could be again opposed by BPC 157). Also, the BPC 157 beneficial effects in rats overdosed with magnesium should be considered with respect to its possible effect on the evidenced Mg2+ homeostasis tightly controlled by maintaining the equilibrium between intestinal Mg2+ absorption and renal Mg2+ excretion/reabsorption and several Mg2+ transporters and channels implicated in Mg2+ absorption and/or re-absorption.